{"id":4688,"date":"2020-05-25T14:21:07","date_gmt":"2020-05-25T14:21:07","guid":{"rendered":"http:\/\/blogs.sld.cu\/oserranob\/?p=4688"},"modified":"2020-05-26T20:14:45","modified_gmt":"2020-05-26T20:14:45","slug":"predictores-de-cancer-de-prostata-hereditario","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2020\/05\/25\/predictores-de-cancer-de-prostata-hereditario\/","title":{"rendered":"Predictores de c\u00e1ncer de pr\u00f3stata hereditario"},"content":{"rendered":"<p style=\"text-align: justify\"><a href=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2020\/05\/Prostate_cancer.jpg\"><img loading=\"lazy\" class=\"alignleft wp-image-4698 size-full\" style=\"border-width: 1px;margin: 5px\" title=\"(c) Pritzlaff M, et al. Genetics in Medicine, 2020\" src=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2020\/05\/Prostate_cancer.jpg\" alt=\"Prostate_cancer\" width=\"85\" height=\"107\" \/><\/a>Los paneles multigenes son recomendables para evaluar a pacientes con riesgo de <a title=\"Informaci\u00f3n de la enfermedad en OMIM\" href=\"https:\/\/omim.org\/entry\/300147\" target=\"_blank\">c\u00e1ncer de pr\u00f3stata hereditario<\/a>, en quienes los antecedentes personales y familiares de tumores de <a title=\"Informaci\u00f3n de la enfermedad en OMIM\" href=\"https:\/\/omim.org\/entry\/114480\" target=\"_blank\">mama<\/a>, <a title=\"Informaci\u00f3n de la enfermedad en OMIM\" href=\"https:\/\/omim.org\/entry\/167000\" target=\"_blank\">ovario<\/a> o <a title=\"Informaci\u00f3n de la enfermedad en OMIM\" href=\"https:\/\/omim.org\/entry\/260350\" target=\"_blank\">p\u00e1ncreas<\/a>, entre otros factores, son predictores de resultados positivos. As\u00ed se reporta en Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, <em>et al<\/em>. <a title=\"Texto completo en ingl\u00e9s\" href=\"https:\/\/www.nature.com\/articles\/s41436-020-0830-5\" target=\"_blank\">Diagnosing hereditary cancer predisposition in men with prostate cancer<\/a>. Genetics in Medicine, 2020; https:\/\/doi.org\/10.1038\/s41436-020-0830-5.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Los paneles multigenes son recomendables para evaluar a pacientes con riesgo de c\u00e1ncer de pr\u00f3stata hereditario, en quienes los antecedentes personales y familiares de tumores de mama, ovario o p\u00e1ncreas, entre otros factores, son predictores de resultados positivos. As\u00ed se reporta en Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, et [&hellip;]<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[11,15,23],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4688"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=4688"}],"version-history":[{"count":4,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4688\/revisions"}],"predecessor-version":[{"id":4699,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4688\/revisions\/4699"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=4688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=4688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=4688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}